

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM323921

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		SECURITY INTEREST	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Nephrogenex, Inc.		11/20/2014	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	East West Bank		
Street Address:	2350 Mission College Blvd., Suite 988		
City:	Santa Clara		
State/Country:	CALIFORNIA		
Postal Code:	95054		
Entity Type:	BANK : UNITED STATES		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2707434	PYRIDORIN	
CORRESPONDENCE DATA			
Fax Number:	4156932222		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4156932000		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		
Address Line 1:	101 California Street, 5th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
ATTORNEY DOCKET NUMBER:	300614-143 NEPHROGENEX		
NAME OF SUBMITTER:	C. Rhem		
SIGNATURE:	/CR/		
DATE SIGNED:	11/20/2014		
Total Attachments: 21			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page1.tif			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page2.tif			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page3.tif			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page4.tif			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page5.tif			
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page6.tif			

CH \$40.00 2707434

source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page7.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page8.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page9.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page10.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page11.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page12.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page13.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page14.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page15.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page16.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page17.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page18.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page19.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page20.tif
source=EWB - NephroGenex - Intellectual Property Security Agreement (executed) - 11.20.14#page21.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** is entered into as of November 20, 2014 by and between EAST WEST BANK ("**Bank**") and NEPHROGENEX, INC., a Delaware corporation ("**Grantor**").

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantor dated of even date herewith (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks and Patents to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement and all other agreements now existing or hereafter arising between Grantor and Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement and under any other agreement now existing or hereafter arising between Grantor and Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

Grantor represents and warrants that Exhibits A, B, and C attached hereto set forth any and all intellectual property rights in connection to which Grantor has registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


GRANTOR:

Address of Grantor:

79 T.W. Alexander Drive
4401 Research Common Building
Suite 290, P.O. Box 14188
Research Triangle Park, NC 27709

Attn: Chief Executive Officer

NEPHROGENEX, INC.

By: 
Name: John P. Hamilton
Title: CFO

BANK:

Address of Bank:

2350 Mission College Blvd., Suite 988
Santa Clara, CA 95054

Attn: Linda LeBeau, Managing Director

EAST WEST BANK

By: _____
Name: _____
Title: _____

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

79 T.W. Alexander Drive
4401 Research Common Building
Suite 290, P.O. Box 14188
Research Triangle Park, NC 27709

Attn: Chief Executive Officer

NEPHROGENEX, INC.

By: _____
Name: _____
Title: _____


BANK:

Address of Bank:

2350 Mission College Blvd., Suite 988
Santa Clara, CA 95054

Attn: Linda LeBeau, Managing Director

EAST WEST BANK

By: 
Name: Linda S. LeBeau
Title: Managing Director,
LIFE SCIENCES

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

<u>Description</u>	<u>Registration Number</u>	<u>Registration Date</u>
--------------------	--------------------------------	--------------------------

None.

EXHIBIT B

Patents

Description	Patent / Application Number	Issue / Application Date
--------------------	--	-------------------------------------

See attached.

Thursday, October 30, 2014

Parent List by Case Number

Page 1

Case Number	SubCase	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Parent Number	Issue Date	Status
03-633 Austria	EP-A1	EPP	04755763.2	18-Jan-2004	1643999	12-Apr-2006	E526023	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Belgium	EP-BE	EPP	04755763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Belgium	EP-BG	EPP	04755763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Canada	CA	PCT	2529538	18-Jan-2004	2529538	29-Dec-2004	2529538	26-Apr-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: Smart & Biggar/Fetherstonhaugh-Groves Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									

Thursday, October 30, 2014

Patent List by Case Number

Case Number	SubCase	Case Type	Application Number	Publication Number	Patent Number	Status
Country			Filing Date	Publication Date	Issue Date	
03-633	EP-CY	EPP	04755763.2	1643999	1643999	Granted
Cyprus, Republic of			18-Jan-2004	12-Apr-2006	28-Sep-2011	
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentsville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes						
03-633	EP-CZ	EPP	04755763.2	1643999	1643999	Granted
Czech Republic			18-Jan-2004	12-Apr-2006	28-Sep-2011	
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentsville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes						
03-633	EP-DK	EPP	04755763.2	1643999	1643999	Granted
Denmark			18-Jan-2004	12-Apr-2006	28-Sep-2011	
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentsville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes						
03-633	EP-EE	EPP	04755763.2	1643999	1643999	Granted
Estonia			18-Jan-2004	12-Apr-2006	28-Sep-2011	
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentsville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes						

Case Number	Sub-Case	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date	Status
03-633	EP	PCT	08755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633	EP-K1	EPP	08755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: Kaiser GY AB Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633	EP-ER	EPP	08755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633	EP-DK1	EPP	08755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									

Thursday, October 30, 2014

Parent List by Case Number

Page 4

Case Number	SubCase	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Parent Number	Issue Date	Status
-------------	---------	-----------	--------------------	-------------	--------------------	------------------	---------------	------------	--------

03-633	EP-GR	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentable
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorney: DSM, IFF
 Client Ref:
 Agent Ref: 130-237 HPGR

03-633	EP-HE	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentable
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorney: DSM, IFF
 Client Ref:
 Agent Ref: 110207-9223 PAKORA

03-633	EP-IE	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentable
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorney: DSM, IFF
 Client Ref:
 Agent Ref:

03-633	EP-IT	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentable
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorney: DSM, IFF
 Client Ref:
 Agent Ref: 125735Eads

Thursday, October 30, 2014

Parent List by Case Number

Page 5

Case Number	SubCase	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Parent Number	Issue Date	Status
-------------	---------	-----------	--------------------	-------------	--------------------	------------------	---------------	------------	--------

03-633	EP-LU	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentanwälte
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorneys: DSH, IFB
 Client Ref:
 Agent Ref:

03-633	EP-MC	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentanwälte
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorneys: DSH, IFB
 Client Ref:
 Agent Ref:

03-633	EP-NL	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentanwälte
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorneys: DSH, IFB
 Client Ref:
 Agent Ref: 996788NL.IF

03-633	EP-PL	EPP	04755763.2	18-Jun-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
--------	-------	-----	------------	-------------	---------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: Witek Tworowska Sulejko & Partners
 Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes
 Attorneys: DSH, IFB
 Client Ref:
 Agent Ref:

Case Number Country	SubCase	Case Type	Application Number Filing Date	Publication Number Publication Date	Patent Number Issue Date	Status
03-633 Portugal	EP-PT	EPP	04755763.2 18-Jun-2004	1643999 12-Apr-2006	1643999 28-Sep-2011	Granted
Assignee: NephroGenex Inc Client: NephroGenex Agent: ZSP Patmanaville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetics						
03-633 Romania	EP-RO	EPP	04755763.2 18-Jun-2004	1643999 12-Apr-2006	1643999 28-Sep-2011	Granted
Assignee: NephroGenex Inc Client: NephroGenex Agent: ZSP Patmanaville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetics						
03-633 Slovakia	EP-SK	EPP	04755763.2 18-Jun-2004	1643999 12-Apr-2006	1643999 28-Sep-2011	Granted
Assignee: NephroGenex Inc Client: NephroGenex Agent: ZSP Patmanaville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetics						
03-633 Slovenia	EP-SI	EPP	04755763.2 18-Jun-2004	1643999 12-Apr-2006	1643999 28-Sep-2011	Granted
Assignee: NephroGenex Inc Client: NephroGenex Agent: ZSP Patmanaville Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetics						

Thursday, October 30, 2014

Patent List by Case Number

Page: 7

Case Number	Sub-Case	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date	Status
03-633 Spain	EP-ES	EPP	04733763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Sweden	EP-SE	EPP	04733763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Switzerland	EP-CH	EPP	04733763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									
03-633 Turkey	EP-TR	EPP	04733763.2	18-Jan-2004	1643999	12-Apr-2006	1643999	28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentanwälte Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes									

Thursday, October 30, 2014

Patent List by Case Number

Case Number Country	Sub-Case	Case Type	Application Number Filing Date	Publication Number Publication Date	Patent Number Issue Date	Status
03-633 United Kingdom	IP-CB	IPP	04755763.2 18-Jan-2004	1643999 12-Apr-2006	1643999 28-Sep-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: ZSP Patentw@lle Title: Pyridoxamine for the Treatment of Diabetic Nephropathy in Type II Diabetes Attorneys: DSRL, FRB Client Ref: Agent Ref:						
03-633 United States of America	ESCOND	DIW	12019819 25-Jan-2008	US-2008-0119525-A1 22-Aug-2008	8667444 29-Nov-2011	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: Title: Pyridoxamine For The Treatment Of Diabetic Intermediates And Post-Amyloid Inhibition Attorneys: DSRL, FRB Client Ref: Agent Ref:						
03-633 United States of America	US-COND	CON	14185312 20-Feb-2014	US-2014-0171472-A1 19-Jan-2014		Published
Assignee: NephroGenex Inc. Client: NephroGenex Agent: Title: Pyridoxamine for the Treatment of Diabetic Kidney Disease Attorneys: DSRL, FRB Client Ref: Agent Ref:						
04-069 United States of America	US	ORD	11/054527 09-Feb-2005	05-0272781 08-Dec-2005	7214789 08-May-2007	Granted
Assignee: NephroGenex Inc. Client: NephroGenex Agent: Title: Methods for the Synthesis of Pyridoxamine Attorneys: DSRL, FRB Client Ref: Agent Ref:						

Thursday, October 30, 2014

Patent List by Case Number

Page: 9

Case Number	SubCase	Case Type	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date	Status
-------------	---------	-----------	--------------------	-------------	--------------------	------------------	---------------	------------	--------

04-099	US-CO2	CON	12855108	12-Aug-2010	US-2010-0305162-A1	02-Dec-2010	8431712	30-Apr-2013	Granted
--------	--------	-----	----------	-------------	--------------------	-------------	---------	-------------	---------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent:
 Title: Methods for the Synthesis of Pyridoxamine

06-099	PCT-EP	PCT	07845980.9	03-Jul-2007	2091114	01-Apr-2009			Published
--------	--------	-----	------------	-------------	---------	-------------	--	--	-----------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent: ZSP Patentanwälte
 Title: Inhibitors Of Advanced Glycation End Products

06-099	US-CO3	CON	14718488	20-Feb-2014	US-2014-0187506-A1	03-Jul-2014			Published
--------	--------	-----	----------	-------------	--------------------	-------------	--	--	-----------

Assignee: NephroGenex Inc.
 Client: NephroGenex
 Agent:
 Title: Inhibitors of Advanced Glycation End Products

Thursday, October 20, 2014 Page: 10

Case Number: SubCase: Application Number: Patent Number: Status: Case Type: Filing Date: Publication Date: Issue Date:

Thursday, October 30, 2014 Page: 10

Report Selection Record Count: 35

Sort Order: by Case Number Report Format: Comprehensive

Print Inventors?: No
Print Remarks?: No
Print Images/Links?: No
Print Designated Countries?: No
Print Licensee(s)?: No

Filing Date: From: To:

Case Number: Status Code: Active Case Type(s): Status(es):
Client: Agent:
Attorney: Assignee: NEDH
Country: Area:
Inventor: Licensee:



United States Patent and Trademark Office

Home | Site Index | Search | Guides | Contacts | eBusiness | eBiz alerts | News | Help



Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 1

Patent #: NONE Issue Dt: Application #: 13935791 ✓ Filing Dt: 07/05/2013
Publication #: 20130295074 ✓ Pub Dt: 11/07/2013
Inventors: Thorsten Degenhardt, Robert Schotzinger, J. Wesley Fox
Title: Pyridoxamine for the Treatment of Diabetic Kidney Disease

Assignment: 1

Reel/Frame: 030950/0151 Recorded: 08/06/2013 Pages: 6

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: EGENHARDT, THORSTEN Exec Dt: 02/01/2012
SCHOTZINGER, ROBERT Exec Dt: 02/01/2012
FOX, J. WESLEY Exec Dt: 02/06/2012

Assignee: NEPHROGENEX, INC. ✓
79 T.W. ALEXANDER DRIVE
RESEARCH COMMONS BUILDING 4401, SUITE 290
RESEARCH TRIANGLE PARK, NORTH CAROLINA 27709-4188

Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
SUITE #3100
CHICAGO, IL 60606

Search Results as of: 11/17/2014 07:40 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350, v.2.5
Web interface last modified: July 25, 2014 v.2.5

{ HOME | INDEX | SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT

http://assignments.uspto.gov/assignments/q?db=pat&qt=pub&reel=&frame=&pat=&pub... 11/17/2014

13/935,791	Pyridoxamine for the Treatment of Diabetic Kidney Disease	03-633-USCON6	11-17-2014::19:38:44
------------	---	---------------	----------------------

Bibliographic Data

Application Number:	13/935,791	Correspondence Address Customer Number:	20306
Filing or 371 (c) Date:	07-05-2013	Status:	Docketed New Case - Ready for Examination
Application Type:	Utility	Status Date:	03-06-2014
Examiner Name:	WESTERBERG, NISSA M	Location:	ELECTRONIC
Group Art Unit:	1618	Location Date:	-
Confirmation Number:	1088	Earliest Publication No:	US 2013-0295074 A1
Attorney Docket Number:	03-633-USCON6	Earliest Publication Date:	11-07-2013
Class / Subclass:	514/183	Patent Number:	-
First Named Inventor:	Thorsten Degenhardt , Durham, NC (US)	Issue Date of Patent:	-
First named Applicant:	INC. NEPHROGENEX , Research Triangle Park, NC (US)	International Registration Number (Hague):	-
Entity Status:	Small	International Registration Publication Date:	-
AIA (First Inventor to File):	No		

Title of Invention:	Pyridoxamine for the Treatment of Diabetic Kidney Disease
---------------------	---

[Close Window](#)

EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration/ Serial Number</u>	<u>Registration/ Application Date</u>
--------------------	--	---

See attached.

Thursday, October 30, 2014

Trademark List by Trademark

Page: 1

Trademark	Case Number	Country	SubCase	Application Number	Publication Number	Registration Number	Status
			Case Type	Filing Date	Publication Date	Registration Date	Next Renewal
PYRIDORIN	99-930	Canada	CA	1121059		09-Jun-2004	Registered 09-Jun-2019
	Owner: NephroFrance Inc Client: NephroFrance Agent: Smart & Biggar/Federalminds@SmartBiggar Classes: 05 Int.						
	Attorney: DSRL JEB Client Ref: Agent Ref:						
PYRIDORIN	99-930	European Community	ECTM	002376133		17-Dec-2002	Registered 14-Sep-2011
	Owner: NephroFrance Inc Client: NephroFrance Agent:						
	Attorney: DSRL JEB Client Ref: Agent Ref: 150152						
PYRIDORIN	99-930	New Zealand	NZ	645598	764	17-Sep-2004	Registered 17-Sep-2018
	Owner: NephroFrance Inc Client: NephroFrance Agent:						
	Attorney: DSRL JEB Client Ref: Agent Ref: 1558028SNZK						
PYRIDORIN	99-930	United States of America	ORD	77487634		15-Apr-2003	Registered 15-Apr-2013
	Owner: NephroFrance Inc Client: NephroFrance Agent:						
	Attorney: DSRL JM Client Ref: Agent Ref:						

Thursday, October 30, 2014

Trademark List by Trademark

Page: 3

Trademark	Case Number	Country	SubCase	Application Number	Publication Number	Registration Number	Status
			Case Type	Filing Date	Publication Date	Registration Date	Next Renewal

Thursday, October 30, 2014

Report Selection

Page: 3

Record Count: 6

Sort Order: by Trademark

Report Format: Comprehensive

Print Goods?: No
 Print Remarks?: No
 Print Images/Links?: No
 Print Designated Countries?: No

Filing Date: From: To:

Case Numbers:

Status Codes: Active

Trademarks:

Case Type(s):

Status(es):

Client:

Agent:

Attorney:

Owner: NEPH

Country:

Area:

Keyword: